Kaiser R, Rauer S
Neurologische Klinik, Albert-Ludwigs-Universität Freiburg, Germany.
Infection. 1999 May-Jun;27(3):177-82. doi: 10.1007/BF02561524.
The sensitivity and specificity of three confirmatory assays for the serodiagnosis of neuroborreliosis were investigated. Samples from 96 patients with proven neuroborreliosis, 80 healthy volunteers, 20 patients with neurosyphilis and 20 patients with recent infections with Epstein-Barr virus (EBV) were tested for borrelial antibodies by immunoblotting, Borrelia burgdorferi sensu lato sonicate EIA following pre-absorption of cross-reactive antibodies (Abs-EIA) and by a so-called RECO-EIA using the following recombinant borrelial proteins as antigens: a 14 kDa-internal flagellin fragment, the outer surface protein C (23 kDa) and the high molecular mass protein p83 (83 kDa). The immunoblots were evaluated according to the criteria published by Engström et al. and Hauser et al. An evaluation of IgM and/or IgG antibodies revealed a considerably higher sensitivity for the RECO-EIA (94%) compared to the Abs-EIA (82%, P < 0.0001). Evaluation of the immunoblot according to the criteria of Hauser was significantly more sensitive than according to the criteria of Engström (89 vs 51%, P = 0.0003). A higher sensitivity was demonstrated for IgM (54 vs 22%) and IgG antibodies (64 vs 24%). When both findings from RECO-EIA and immunoblotting were considered, positive findings in the first step assay (sonicate EIA without pre-absorption) were confirmed in 97% of patients. When samples were tested for IgM antibodies, the specificities of the three confirmatory assays did not differ significantly, but in the case of IgG antibodies, the immunoblot (Hauser: P = 0.013; Engström: P = 0.004) and the RECO-EIA (P = 0.02) were more specific than the Abs-EIA. It is concluded that the immunoblot (evaluated according to Hauser) and the RECO-EIA are both suitable as confirmatory assays in the serological diagnosis of neuroborreliosis. Monoclonal antibodies are mandatory tools in the evaluation of the immunoblot.
研究了三种用于神经型莱姆病血清学诊断的确证试验的敏感性和特异性。对96例确诊的神经型莱姆病患者、80名健康志愿者、20例神经梅毒患者和20例近期感染爱泼斯坦-巴尔病毒(EBV)的患者的样本进行检测,通过免疫印迹法、交叉反应抗体预吸附后的伯氏疏螺旋体广义株超声裂解物酶免疫测定(Abs-EIA)以及使用以下重组伯氏疏螺旋体蛋白作为抗原的所谓RECO-EIA检测伯氏疏螺旋体抗体:一个14 kDa的内部鞭毛蛋白片段、外膜蛋白C(23 kDa)和高分子量蛋白p83(83 kDa)。根据Engström等人和Hauser等人发表的标准对免疫印迹进行评估。对IgM和/或IgG抗体的评估显示,与Abs-EIA(82%,P<0.0001)相比,RECO-EIA的敏感性显著更高(94%)。根据Hauser标准对免疫印迹的评估比根据Engström标准更敏感(89%对51%,P = 0.0003)。IgM(54%对22%)和IgG抗体(64%对24%)表现出更高的敏感性。当同时考虑RECO-EIA和免疫印迹的结果时,第一步检测(未预吸附的超声裂解物酶免疫测定)中97%的患者得到了阳性结果。当检测样本中的IgM抗体时,三种确证试验的特异性没有显著差异,但对于IgG抗体,免疫印迹(Hauser标准:P = 0.013;Engström标准:P = 0.004)和RECO-EIA(P = 0.02)比Abs-EIA更具特异性。结论是,免疫印迹(根据Hauser标准评估)和RECO-EIA均适用于神经型莱姆病血清学诊断的确证试验。单克隆抗体是评估免疫印迹的必备工具。